Managing My Cancer

Why Cancer is Caused by Gene Mutations

About 300-400 genes among the 20,000 human genes are related to cancer, and cancer is caused by germline or somatic mutations in those cancer-related genes. For example, if a gene controlling growth is mutated, the genetically altered cell may start to abnormally proliferate and cause the formation of a tumor. Patients with different cancer types may have the same genetic alterations .


Target Cancer Gene Mutations by Precision Medicine

Through the ever advancing progress of medicine, it is now known that using certain treatment strategies can have a more significant treatment effect for patients with specific genetic mutations. Precision medicine can surpass current treatment plans that are only based on cancer types and instead utilizes genetic testing to identify the mutated genes and provide precise treatment strategies. Thus, cancer can be managed more efficiently, avoiding unnecessary side effects and empowering physicians and patients to gain valuable time.


Treat Cancer Gene Mutations Through Precision Medicine

An approach that can yield a better outcome is a personalized treatment tailored for your individual cancer. Researchers and physicians have discovered that there is a strong association between the genomic alterations of a patient’s tumor and the success of using tailored targeted therapies. More and more of these targeted therapies are used in the clinic with impressive success, and are prescribed based on a patient’s tumor genomic alterations. Those therapies are already commonly used for some cancer types, such as for lung cancer. However, patients with a wide variety of cancer types can find a suitable targeted treatment through tumor genomic testing. By performing comprehensive genomic testing, ACT Genomics provides you with the most promising tailored treatment options to help you fight your cancer.


Act now and manage your cancer from cancer prevention, cancer treatment, cancer monitoring and immunotherapy evaluation through genomic testing.

Cancer Treatment

Why do I need genetic testing to treat my cancer?

The latest cancer treatment perspective is Precision Medicine. Using cancer genomic testing to treat cancer provides a breakthrough in current cancer type-based treatment strategies, and identifies more appropriate treatment options according to the cancer’s genomic mutation profile. According to the World Cancer Foundation, the most common cancers worldwide in 2012 were lung cancer, breast cancer, colorectal cancer and prostate cancer. Patients with different cancer types may harbor the same genetic mutations, while different genetic mutations may occur in patients of the same cancer type. For this reason, effective treatment strategies may be used cross various cancer types, and genetic mutation-based treatment plans are very precise. For example, genomic testing can identify breast cancer patients who are likely to benefit from drugs approved for prostate cancer. Cancer genomic profiles may be complicated and new mutations may emerge fast. Comprehensive cancer genomic profiling services analyze the cancer genomic profile to provide more effective treatment options and guide clinical decisions even in patients with drug resistance, relapse and metastasis.


If you would like to have a comprehensive evaluation of immunotherapy, targeted therapy, hormone therapy and chemotherapy choices, you may consider using our comprehensive genomic profiling service: ACTOnco®+

If you would like to have an evaluation of targeted therapy choices, you may consider using our target genomic profiling service: ACTDrug®+

If you would like to have a treatment evaluation for specific dugs, you may consider using our BRCA1/2 test ACTBRCA™


Cancer Monitoring

How do I monitor my cancer after treatment?

Cancer needs to be monitored in different periods for different purposes, such as to detect if the tumor is totally removed after a surgery, check if the tumor is shrinking or becoming bigger, monitor drug resistance, and prevent cancer recurrence. Traditional ways to monitor cancer includes using blood tests to check the tumor proteins levels, such as the carcinoembryonic antigen (CEA) test, and conducting radio imaging examination such as regular chest x-rays and CT scans. A new cancer monitoring technology is to use liquid biopsy to directly detect circulating tumor DNA, ctDNA in the blood. ctDNA can indicate tumor dynamics before it can be observed by traditional methods. Monitoring ctDNA through genomic testing can detect genetic mutations correlated with drug resistance, provide assessment on treatment responses and early detection for cancer recurrence. Our ACTMonitor™ genomic testing can help you to track treatment results, increase treatment effectiveness, and detect cancer recurrence .

If you would like to monitor your treatment more effectively, you may consider using our cancer monitoring service, ACTMonitor ™

Immunotherapy Evaluation

Do I benefit from Immunotherapy?

Immunotherapy is a type of cancer treatment that helps your immune system to fight cancer. Immune checkpoint inhibitors are drugs that can help T-cells to recognize and attack cancer cells. However, without immunotherapy-specific analysis, only 20% to 30% of patients are likely to benefit from immune checkpoint inhibitors, their efficacy varies among different tumor types and depends on genomic alternations in cancer cells.

Therefore, it is critical to have an accurate method to predict the response to these drugs. To evaluate if you are likely to benefit from therapy with immune checkpoint inhibitors, you may consider using our immunotherapy prediction genomic test ACTOnco™.

Cancer Prevention

Have I inherited mutations of cancer-related genes?

Approximately 5-10% of cancers are hereditary, and the most common hereditary cancers are breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer and kidney cancer. Hereditary cancers are caused by mutations in cancer-related genes. Many of these genes help repair damaged DNA, and when these genes do not function correctly, more genetic alterations may develop and cause cancer. Examples for such genes are BRCA1/2, and BRCA1/2 mutations increases the risk of developing breast cancer, ovarian cancer, prostate cancer and pancreatic cancer. Understanding the hereditary cancer risk enables high-risk individuals to start taking actions for cancer prevention and early detection.


ACTRisk™ is a genetic test that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with high-risk individuals.

Patient Stories

Mr. Yu, Taiwan

Mr. Yu, Taiwan

Stage 4 Lung Cancer Survivor

“Cancer completely changed my perspective on life. Now I focus on enjoying life and trying to make the most out of every day. I’m glad my doctor told me about comprehensive genomic profiling that found more treatment options for me.”

Andrew Tay, MD

A liver cancer survivor in Singapore

“To date I have done three rounds of Genomic Profiling Analysis semi-annually to monitor my liver tumor genes mutation activities. In case I have a recurrence, or develop a secondary cancer, I will stand a better chance to treat it at early stage.”

Service Process

Service Overview

1 Turnaround time is counted after the received sample passes ACT Genomics sample quality control test
2 Formalin-fixed and paraffin-embedded (FFPE)
3 Peripheral blood mononuclear cell (PBMC)



Understanding Precision Medicine

Genes are DNA sequences that carry hereditary information. This information defines the traits of a cell and is necessary to maintain normal cell functions. Humans have approximately 20,000 genes.
A gene mutation is a permanent change in the sequence of chemical bases in a cell’s DNA. Mutations occur frequently in the human body. Some mutations are not harmful, but other mutations may cause the proteins encoded by the gene to function incorrectly or not at all. This, in turn, prevents the cell from working properly and can cause diseases such as cancer.
Among the 20,000 human genes, about 300-400 are related to cancer. If a mutation occurs in one of those genes, this may cause an uncontrolled growth of the affected cell by a dysregulation of the cell growth signaling pathway in which the mutated gene plays a role. Since patients have their own individual mutation patterns affecting different genes and pathways, targeted therapy only works for patients in which the targeted pathways are altered.
Precision medicine analyzes mutations in cancer-related genes to find out what drives your cancer, enabling the identification of targeted therapies that directly interfere with tumor growth. Because gene mutations are different for individual patients, you are more likely to benefit from therapies that are tailored for your cancer.
The mutations in cancer-related genes are identified by an analysis of tumor samples using a high-throughput method called next-generation sequencing (NGS). This method allows a rapid and comprehensive gene analysis. Through bioinformatics data processing and utilizing clinical databases, gene mutations are matched with the appropriate targeted therapies to provide patients and doctors with personalized treatment options.